About Furiex
Furiex is a company based in Morrisville (United States) founded in 2009 was acquired by Actavis in April 2014. Furiex offers products and services including RINVOQ and TrenibotulinumtoxinE. Furiex operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, RedHill Biopharma, Cosmo Pharmaceuticals and Alcresta, among others.
- Headquarter Morrisville, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Furiex Pharmaceuticals, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Furiex
Furiex offers a comprehensive portfolio of products and services, including RINVOQ and TrenibotulinumtoxinE.
Treats adults with giant cell arteritis and other inflammatory conditions.
Addresses glabellar lines with rapid onset action.
Funding Insights of Furiex
Detailed funding history for Furiex
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Furiex
Furiex has secured backing from 1 investor. Prominent investors backing the company include Actavis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer of generic products
|
Locked | Locked | Locked |
Investor details for Furiex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Furiex
Investment portfolio details for Furiex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Furiex
Detailed financials for Furiex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Furiex Comparisons
Peer comparison for Furiex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Furiex
Furiex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, RedHill Biopharma, Cosmo Pharmaceuticals and Alcresta, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal diseases are developed and provided.
|
|
| Locked | Locked | Locked |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
Detailed competitors of Furiex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Furiex
Complete news archive for Furiex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Furiex
Furiex was founded in 2009.
Furiex is headquartered in Morrisville, United States.
Furiex Pharmaceuticals was established in 2009 in Morrisville, United States, within the pharmaceutical sector. Focus was placed on developing eluxadoline, a mu opioid receptor agonist and delta opioid receptor antagonist, targeted at diarrhea-predominant irritable bowel syndrome. Two Phase III clinical trials were completed in 2014, meeting primary endpoints for stool consistency and abdominal pain improvements as agreed with FDA and EMA. Acquisition by Actavis occurred in 2014.
Furiex's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Furiex offers RINVOQ and TrenibotulinumtoxinE.
Furiex has 1 investor. Key investors include Actavis.